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At birth, when immune responses are insufficient, there begins the development of the 28 
defence capability against pathogens. Leptin and adiponectin, adipokines which are 29 
present in breast milk, have been shown to play a role in the regulation of immune 30 
responses. We report here, for the first time, the influence of in vivo adipokines 31 
supplementation on the intestinal immune system in early life. Suckling Wistar rats were 32 
daily supplemented with leptin (0.7 μg/kg/day, n = 36) or adiponectin (35 μg/kg/day, 33 
n = 36) during the suckling period. The lymphocyte composition, proliferation and 34 
cytokine secretion from mesenteric lymph node lymphocytes (on days 14 and 21), as well 35 
as intestinal IgA and IgM concentration (day 21), were evaluated. At day 14, leptin 36 
supplementation significantly increased the TCRαβ+ cell proportion in mesenteric lymph 37 
nodes, in particular due to an increase in the TCRαβ+ CD8+ cell population. Moreover, 38 
the leptin or adiponectin supplementation promoted the early development CD8+ cells, 39 
with adiponectin being the only adipokine capable of enhancing the lymphoproliferative 40 
ability at the end of the suckling period. Although leptin decreased intestinal IgA 41 
concentration, it had a trophic effect on the intestine in early life. Both adipokines 42 
supplementation modulated the cytokine profile during (day 14) and at the end (day 21) 43 
of the suckling period. These results suggest that leptin and adiponectin during suckling 44 




1. Introduction 47 
During human foetal development, the immune system is adapted to the intrauterine 48 
environment(1). The transition from practically sterile environment in the uterus to the 49 
outside world is particularly critical because the neonate is suddenly newly exposed to a 50 
large number of microorganisms and food antigens. Therefore, the development of the 51 
human immune system undergoes the most radical and rapid changes. However, during 52 
the first months of life this system is still immature and, in consequence, there are high 53 
morbidity and mortality rates due to infectious diseases(2). 54 
In the human and rat newborn, the immature immune system has significant quantitative 55 
and qualitative deficiencies, especially concerning acquired immunity. The 56 
underdeveloped acquired immunity is reflected by the existence of low immunoglobulin 57 
(Ig) levels, and the small number of naive T lymphocytes and antigen-presenting cells 58 
(APC) in the newborn of both species(3,4). For this reason the survival of the human and 59 
rat neonate relies on the innate immune system(5,6). However, this still has some 60 
deficiencies, such as low phagocytic activity, defects in neutrophil and monocyte 61 
numbers and function, reduced cytokine secretion and lower natural killer (NK) cytotoxic 62 
capacity compared to those present in adults(7). On the other hand, physical barriers, such 63 
as the intestinal wall, are crucial for the human and rat neonate to avoid infections and 64 
control exposure to oral antigens, which in turn is a challenge for the development and 65 
maturation of the gut-associated lymphoid tissue (GALT)(4,8). GALT, formed by the 66 
inductive sites (Peyer’s patches, isolated lymph nodes, and mesenteric lymph nodes 67 
(MLN)) and the effector sites (intraepithelial and lamina propria lymphocytes), is not 68 
mature at birth in both species and develops in the postnatal period(9–11).  69 
In humans, to compensate the immunological immaturity in intrauterine and early life, 70 
the mother provides important factors for protecting the newborn. Firstly, transferring 71 
antibodies through the placenta and, later, through the breast milk(12). Human milk 72 
contains a wide variety of bioactive factors and hormones(13) including adipokines, such 73 
as leptin and adiponectin. The concentration of these adipokines in breast milk change 74 
throughout the lactation(14,15). Leptin and adiponectin are involved in the control of 75 
endocrine and metabolic systems and they seem to play a role in the regulation of the 76 
immune system, in both the innate and adaptive immune responses(16,17). In particular, 77 
leptin has been described as a pro-inflammatory cytokine that stimulates proliferation and 78 
NK cell and T lymphocyte responses, and the switch to a pro-inflammatory Th1 79 
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immunity, thus promoting the secretion of cytokines such as interferon (IFN)-γ, tumour 80 
necrosis factor (TNF)-α, interleukin (IL)-6 and IL-1(17). However, the  anti- or pro-81 
inflammatory properties of adiponectin are still a matter of discussion(18). It has been 82 
described that adiponectin has an anti-inflammatory function because of its capacity to 83 
suppress the synthesis of TNF-α and IFN-γ and to induce the production of several anti-84 
inflammatory cytokines(19). In contrast, other studies show an inflammatory response 85 
under certain circumstances, by activating NK cells and inducing inflammatory cytokines 86 
such as IL-1 and IL-6(20,21).  87 
To date, there is little data available about the dietary effects of leptin and adiponectin on 88 
the GALT, and none about the effect of either adipokines in this compartment in early 89 
life, when the development of the immune system is taking place. We hypothesized that 90 
these breast milk adipokines, with immunomodulatory actions described in adults, may 91 
play also role in the neonatal immune system, and in particular in the maturation of the 92 
GALT. Therefore, the aim of the present study was to evaluate the impact of leptin or 93 
adiponectin supplementation on some aspects of the intestinal immune system 94 
development in neonatal rats. Specifically, we focused on the MLN lymphocytes, both in 95 
terms of their composition and functionality. Thus, immune responses of pups fed with 96 
leptin or adiponectin at the middle and at the end of the suckling period were established. 97 
2. Materials & Methods 98 
2.1. Animals 99 
Sixteen pregnant Wistar rats (G15) were obtained from Janvier Labs (Le Genest Saint 100 
Isle, France) and individually housed in cages under controlled conditions of temperature 101 
and humidity in a 12 h light–12 h dark cycle in the Faculty of Pharmacy and Food Science 102 
animal’s facilities. Rats were fed with commercial diet corresponding to the American 103 
Institute of Nutrition 93M formulation and water ad libitum.  104 
The studies were performed in accordance with the criteria outlined by the Guide for the 105 
Care and Use of Laboratory Animals. Experimental procedures were reviewed and 106 
approved by the Ethical Committee for Animal Experimentation of the University of 107 
Barcelona (CEEA/UB ref. 220/15). 108 
2.2. Experimental design and dietary supplementation  109 
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Pregnant rats were allowed to deliver naturally. The day after birth was registered as day 110 
1 of life. Litters were unified to 9 pups per lactating dam, with free access to the nipples 111 
and rat diet. Handling was performed in the same time range to avoid the influence of 112 
biological rhythms.  113 
According to the oral supplementation given, suckling rats were distributed into four 114 
groups (n = 36/group): reference, leptin, adiponectin and whey protein concentrate 115 
(WPC). Each group was composed of four litters of 9 pups each. Leptin group were 116 
administered with 0.7 μg/kg/day of leptin (i.e. 17.6, 26.6 and 43.8 ng/rat at days 10, 14 117 
and 21, respectively) (PeproTech®, Rocky Hill, NJ, USA) in water, based on a reported 118 
study(22). Due to the lack of similar studies, the adiponectin dose was calculated taking 119 
into account the concentration ratio of adiponectin vs. leptin in human milk, which was 120 
about 50 times higher(23,24). Therefore, the adiponectin group was supplemented with a 121 
solution of 35 μg/kg/day of adiponectin (PeproTech®) in water (i.e. 0.8, 1.2 and 2.1 g/rat 122 
at days 10, 14 and 21, respectively). In parallel, another group of animals was 123 
administered with a bovine WPC, containing high concentration of bioactive factors. This 124 
WPC was similar to that used in previous studies and it did show immunomodulatory 125 
effects on neonatal rats(25,26). Thus, this intervention was used as a possible positive 126 
control of modulation by breast milk bioactive factors. Animals from the WPC group 127 
were supplemented with Lacprodan® MFGM-10 (Arla Foods Ingredients Group, Diby, 128 
Denmark) in a previously described physiological dose for suckling rats receiving infant 129 
formula(26) (0.3 g/kg/day) (i.e. 6.9, 10.8 and 17.9 mg/rat at days 10, 14 and 21, 130 
respectively). The reference group was administered with the same volume of vehicle 131 
(water) as the supplemented groups (10 mL/kg/day). To allow gastric emptying, litters 132 
were separated from their dam half an hour before oral supplementation. Meanwhile 133 
animals were weighed. Pups received the supplements daily by oral gavage throughout 134 
the suckling period (from day 1 to 21) using low-capacity syringes (Hamilton Bonaduz, 135 
Bonaduz, Switzerland) adapted to oral 25- or 23-gauge gavage tubes (ASICO, Westmont, 136 
IL, USA), as previously described(25). 137 
Body weight was recorded throughout the study, and on the last day body length 138 
(nose-anus) was measured. The body weight gain percentage at a specific day was 139 
calculated by subtracting the weight at the beginning of the study (day 1) from the weight 140 
at the subsequent days, divided by starting weight and multiplied by 100. These measures 141 
enabled the determination of the body mass index (BMI), calculated as body 142 
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weight/length2 (g/cm2) and the Lee index, calculated as 3√ weight/length x 1000 143 
(3√g/cm).  144 
2.3. Sample collection and processing 145 
At days 10, 14 and 21, animals were intramuscular anaesthetized with ketamine 146 
(90 mg/kg) (Merial Laboratories S.A., Barcelona, Spain) and xylazine (10 mg/kg) (Bayer 147 
A.G., Leverkusen, Germany), exsanguinated, and MLN and small intestine (SI) were 148 
collected. The duodenum was removed and the distal 1/3 portion of the remaining 149 
intestine was used to obtain the gut wash. For this, it was opened lengthwise, cut into 5 150 
mm pieces, weighed, and incubated with 2 mL of phosphate buffer solution (PBS pH 7.2; 151 
154 mM sodium chloride (NaCl), 3.99 mM sodium dihydrogen phosphate monohydrate 152 
(NaH2PO4·H2O), 16 mM disodium hydrogen phosphate dehydrate (Na2HPO4·2H2O)) for 153 
15 min in a shaker (55 u/min) at 37 °C. After centrifugation (535 g, 5 min, 4° C), 154 
supernatants were stored at -20 °C until Ig quantification. 155 
2.4. Immunoglobulin quantification 156 
At the end of the suckling period, intestinal IgA and IgM concentrations were quantified 157 
in gut wash using a rat IgA or IgM enzyme-linked immunosorbent assay (ELISA) 158 
quantification set (Bethyl Laboratories, Montgomery, TX, USA), as performed in 159 
previous studies(27). Data are expressed as μg of IgA or IgM per g of intestinal tissue used 160 
for the gut wash. 161 
2.5. Lymphocyte isolation from mesenteric lymph nodes 162 
MLN cell suspensions were obtained by passing the tissue through a sterile 40 µm mesh 163 
cell strainer (Thermo Fisher Scientific, Barcelona, Spain). The cell suspension was 164 
centrifuged (538 g, 10 min, 4 °C) and resuspended in Roswell Park Memorial Institute 165 
(RPMI) 1640 medium (Sigma-Aldrich, Madrid, Spain) enriched with 10% foetal bovine 166 
serum (FBS; Sigma-Aldrich), 100 IU/mL streptomycin-penicillin (Sigma-Aldrich), 167 
2 mM L-glutamine (Sigma-Aldrich) and 0.05 mM 2-β-mercaptoethanol (Merck 168 
Millipore, Darmstadt, Germany). Cell counting and viability were assessed by 169 
CountessTM Automated Cell Counter (InvitrogenTM, Thermo Fisher Scientific). 170 
Lymphocytes were immediately used to analyse their phenotype and their ability to 171 
proliferate and secrete cytokines after mitogen stimulation. 172 
2.6. Lymphocyte immunofluorescence staining and flow cytometry analysis 173 
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Lymphocytes (2–5 x 105) from MLN were stained with anti-rat monoclonal antibodies 174 
(mAb) conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), 175 
peridininchlorophylla protein (PercP), allophycocyanin (APC) or APC-cyanine (Cy)7, as 176 
in previous studies(28). In this case, the mAb used were anti-CD4, anti-CD8α, anti-CD8β, 177 
anti-TCRαβ, anti-TCRγδ, anti-NKR-P1A, anti-CD25, anti-CD45RA (BD Biosciences, 178 
San Diego, USA), anti-CD62L and anti-CD103 (Biolegend, San Diego, CA, USA), anti-179 
TLR-4 (Novus Biologicals, Littlon, CO, USA), anti-Foxp3 (eBioscience, Frankfurt, 180 
Germany). The cells were incubated with a mixture of optimal concentrations of mAb in 181 
PBS containing 2% FBS and 0.1% sodium azide (Merck Millipore), for 20 min at 4 °C in 182 
darkness. A negative control staining using an isotype-matched mAb was included in 183 
each cell sample. For intracellular staining, cells previously labelled with anti-CD4-PE 184 
and anti-CD25-FITC mAb were treated with Foxp3 fixation/permeabilization kit 185 
(eBioscience). Then, intracellular staining with anti-Foxp3-APC mAb was carried out 186 
under the same conditions as extracellular staining. All stained cells were fixed with 0.5% 187 
p-formaldehyde and stored at 4 °C in darkness until analysis by flow cytometry. Analyses 188 
were performed using a GalliosTM flow cytometer (Beckman Coulter Inc., Miami, FL, 189 
USA) in the Scientific and Technological Centres of the University of Barcelona (CCiT-190 
UB). All samples were assessed by FlowJo version 10 software (TreeStar, Inc., Ashland, 191 
OR, USA). Results are expressed as percentages of positive cells in the lymphocyte 192 
population selected according to their forward-scatter characteristics (FSC) and side-193 
scatter characteristics (SSC) or in a particular selected population. 194 
2.7. Lymphocyte proliferative response 195 
T lymphocytes activation was carried out in 96-well plates (TPP, Trasadingen, 196 
Switzerland) previously coated with anti-CD3/anti-CD28 mAb (10 µg/mL and 20 µg/mL, 197 
respectively, BD Biosciences). MLN lymphocytes (105/200 µL) from 14-day- and 21-198 
day-old animals were incubated in quadruplicate with or without stimulus for 48 h. The 199 
proliferation was quantified by means of the BrdU Cell Proliferation Assay Kit (Merck 200 
Millipore) following the manufacturer’s instructions. This assay is based on the 201 
measurement of 5-bromo-2’-deoxyuridine (BrdU) incorporated into proliferating cells 202 
during DNA synthesis. After stopping the enzymatic reaction, the absorbance (Ab) was 203 
measured at 450 nm on a microplate photometer (Labsystems Multiskan MS). 204 




Proliferation rate (%) = (A/B) x 100, where,  207 
A = [(Abstimulated cells – Abnon-stimulated cells) / Abnon-stimulated cells]supplemented group 208 
B = [(Abstimulated cells – Abnon-stimulated cells) / Abnon-stimulated cells]reference group 209 
2.8. Quantification of cytokine production from MLN lymphocytes 210 
Supernatants collected after the stimulation process described above were used to 211 
quantify cytokine production. Concentrations of IL-1α, IL-2, IL-4, IL-5, IL-10, IL-12p70, 212 
IL-13, IL-17A, IFN-γ and TNF-α were quantified using ProcartaPlex® Multiplex 213 
Immunoassay (eBioscience). In brief, specific magnetic capture beads coded with distinct 214 
colours were bound to the analyte of interest. Then it was possible to reveal the specific 215 
concentration through different detection antibodies conjugated to PE by the Luminex 216 
MAGPIX analyser (Luminex®, Austin, TX, USA) at the CCiT-UB.  217 
The lower limits of detection were: 13 pg/mL for IL-1α; 2.10 pg/mL for IL-2; 0.85 pg/mL 218 
for IL-4; 1.65 pg/mL for IL-5; 14 pg/mL for IL-10; 4.93 pg/mL for IL-12p70; 3.17 pg/mL 219 
for IL-13; 2.61 pg/mL for IL-17A; 4.35 pg/mL for IFN-γ; and 3.08 pg/mL for TNF-α. 220 
2.9. Statistical analysis 221 
Analysis of the data was carried out by the software package IBM Statistical Package for 222 
the Social Sciences (SPSS, version 22.0, Chicago, IL, USA). To assess the homogeneity 223 
of variance and the distribution of the results, Levene’s and Shapiro–Wilk tests were 224 
performed, respectively. Repeated measures analysis of variance using the Bonferroni 225 
correction was used to determine the time-related differences in the body weight in each 226 
supplementation. For other variables, when there was a normal distribution and equality 227 
of variance, conventional one-way ANOVA test followed by the post hoc Bonferroni was 228 
performed. Non-parametric Kruskal–Wallis test followed by the post hoc Mann–Whitney 229 
U test were used in order to assess significance. Significant differences were established 230 
at P<0.05. 231 
3. Results 232 
3.1. Growth and morphometry 233 
Rats’ body weight gain, calculated by monitoring from the day after birth and throughout 234 
the suckling period, showed no differences among groups (Suppl. Fig. 1). Morphometric 235 
variables such as BMI and Lee index were also evaluated during suckling (Table 1). The 236 
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age-increasing BMI pattern was not modified by any of the supplementations. However, 237 
while the Lee index was not affected by the diets in any of the groups at 10 and 14 days, 238 
a decrease was seen at day 21 (P<0.01) in all groups (Table 1). 239 
Although relative weight of the small intestine, expressed as percentage with respect body 240 
weight, increased mainly the last week of the suckling period (Table 1), the relative length 241 
decreased all along this period. Moreover, leptin displayed an intestinal growth-242 
enhancing effect at day 21 (P<0.05 vs. reference group). 243 
3.2. Intestinal secretory IgA and IgM concentration 244 
Intestinal secretory IgA and IgM production was established on day 21 (Fig. 1). In the 245 
reference group, secretory IgA concentration was five times higher than that of IgM 246 
(Fig. 1). Leptin dietary supplementation significantly lowered the secretory IgA content 247 
in the intestinal compartment (P<0.01 vs. reference group) (Fig. 1). With regard to IgM, 248 
none of the three experimental supplementations modified the levels of this Ig (Fig. 1). 249 
3.3. Lymphocyte composition of mesenteric lymph nodes 250 
A mean count of 2.0 x106 ± 2.0 x105 and 1.3 x107 ± 7.6 x105 of MLN cells were 251 
established during (day 14) and at the end (day 21) of the suckling period, respectively, 252 
from all groups, without differences among them. Their main lymphocyte subsets 253 
proportions are shown in (Table 2). Leptin and WPC supplementations significantly 254 
increased the T cell proportion compared with the reference group at day 14 (P<0.01 and 255 
P<0.05, respectively). These increases were due to a higher proportion of TCRαβ+ cells 256 
(P<0.01 and P<0.05, respectively), and in particular to an increase in the TCRαβ+ CD8+ 257 
cell population (P<0.05) (Table 2).  258 
Although no significant effects were observed in TCRγδ+ cell proportions as a result of 259 
adipokine supplementation, an age-increasing proportion was found in the reference  260 
group that was particularly due to the increase in the TCRγδ+ CD8+ cell proportion 261 
(P<0.01). This was not the case for the rest of the groups in which the values observed at 262 
day 14 were already as high as those found on day 21 (Table 2). With regard to NK subset, 263 
a relative age-associated decrease was detected between 14- and 21-day-old rats due to a 264 
normal immune development in all groups. This decrease is also found in the proportion 265 
of NK CD8+ cells in MLN from leptin animals between day 14 and day 21, but not in the 266 
others. NK cell percentages at day 14 or at day 21 were not influenced by dietary 267 
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supplementation. On the other hand, the leptin group showed a decrease from day 14 to 268 
day 21 in NKT cell proportion in parallel to a decrease in NKT cells expressing CD8 269 
coreceptor (Table 2). 270 
In reference animals the whole proportion of CD8+ cells in MLN increased from day 14 271 
to day 21 of age (p<0.05) (Fig. 2a). In contrast, both adipokines induced a higher 272 
proportion of CD8+ cells on day 14 (p<0.05 vs. reference) and on that day, they were able 273 
to promote the achievement of a percentage of CD8+ cells that was typical from day 21 274 
(Fig. 2a). When looking at both forms of CD8 coreceptor (CD8αα and CD8αβ), a decrease 275 
in the CD8αα+/CD8αβ+ ratio in the reference and leptin groups was observed in 276 
comparison to their respective group at day 14 (P<0.01) (Fig. 2b).  277 
The three dietary interventions did not modify the proportion of the other main 278 
subpopulations in the MLN compartment, such as Th, Treg, B and CD8+CD4+ cells, 279 
either at day 14 or day 21 of life (Table 2). The activation marker CD25 was also studied 280 
in the main subsets and in all cases its percentage was about 4%, without differences 281 
among groups or ages studied. 282 
For the study of the intestinal homing, the expression of adhesion molecules CD62L 283 
selectin and αE integrin (CD103) was quantified. CD62L selectin was highly expressed 284 
in MLN cells at day 21, whereas αE integrin was poorly expressed (Suppl. Fig. 2). No 285 
significant differences were detected in the CD62L/αE integrin expression pattern due to 286 
the supplements in any studied group within each studied day (Suppl. Fig. 2). However, 287 
αE- CD62L+ cell percentages at day 21 from the reference, leptin and WPC groups (61.5 288 
± 1.7; 60.9 ± 1.6; 58.9 ± 1.3, respectively) were higher than their respective value at day 289 
14 (52.9 ± 1.7; 54.5 ± 2.6; 50.9 ± 1.2, respectively) (P<0.05). In contrast, the adiponectin 290 
group showed no differences at day 14 and 21.  291 
In addition, the expression of CD62L selectin/αE integrin molecules on T and B cells was 292 
also studied (Suppl. Table 1). No significant differences were detected between groups in 293 
Th (CD4+CD8-), Tc (CD8+CD4-), DP (CD4+CD8+) and B (CD45RA+) lymphocytes 294 
on the same day of analysis, with the exception of the changes found in the CD4+CD8+ 295 
subset at day 21, where leptin and WPC supplementation decreased the αE+CD62L+ 296 
percentage (p<0.05 vs. reference). Moreover, some statistical differences between day 14 297 
and day 21 were found in Th and B subsets within their respective group. In this regard, 298 
the low αE-CD62L+ cell percentage in the adiponectin group found on day 21 (Suppl. 299 
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Fig. 2) could be explained by the relative increase in the percentage of CD4+ αE+CD62L- 300 
and CD4+ αE+CD62L+ (Suppl. Table 1).  reference, adiponectin and WPC groups, but 301 
not the leptin group, showed some age-developmental CD62L/αE integrin changes in the 302 
B cell subset. In Tc cells no differences were found due to age or supplementations 303 
(Suppl. Table 1). 304 
3.4. Mesenteric lymph node lymphocyte proliferation 305 
To determine the functional capacity of MLN lymphocytes, we studied their 306 
lymphoproliferative response on days 14 and 21. At day 14, proliferative capacity was 307 
not modified by any supplementation (Fig. 3). At the end of the suckling period, 308 
adiponectin and WPC supplementation showed higher lymphoproliferative capacity than 309 
the reference group (P<0.05), whereas it was not modified by the leptin supplementation 310 
(Fig. 3). 311 
3.5. Cytokine production by mesenteric lymph node lymphocytes 312 
The cytokine pattern secreted by MLN cells differed between cells obtained at day 14 and 313 
21 of age (Table 3). Cell culture supernatant from the reference group on day 21 showed 314 
lower IL-1α, IL-10, IL-13 and higher TNF-α concentrations than those quantified on day 315 
14, while IL-10/TNF-α was particularly low on day 21 due to the decrease in IL-10.  316 
All three supplementations showed the same profile as that observed in the reference 317 
group for IL-1, IL-10 and IL-10/TNF-α. Leptin and adiponectin supplementation were 318 
able to lower the levels of IL-13 from day 21 to those observed at day 14. Moreover, apart 319 
from the reference group, only adiponectin was able to lower TNF-α to the values present 320 
at day 14. In addition, IL-4 and IL-5 concentrations at day 21 were lower than those at 321 
day 14 in the leptin and adiponectin groups, an effect not observed in the reference group.  322 
At day 14, the leptin supplementation group showed higher IL-4 and IL-5 release, being 323 
both Th2-related cytokines, than the reference group (P<0.05) (Table 3). In contrast, 324 
lymphocytes from the adiponectin group produced significantly higher levels of IL-5, 325 
IL-13 and TNF-α at day 14 than the reference group at the same day (P<0.01) (Table 3).  326 
At day 21, the leptin and adiponectin groups showed a notable decrease in IL-2 secretion 327 
in comparison to the reference group (P<0.01). The IL-12p70 secretion was also 328 
diminished by the three supplementations (P<0.05 in leptin group and P<0.01 in 329 
adiponectin and WPC vs. reference group) (Table 3). In addition, IL-13 concentration 330 
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from animals supplemented with adiponectin was lower than that produced by the 331 
reference group (P<0.01).  332 
Overall, the Th1/Th2 cytokine (INF-γ/IL-4) ratio was not influenced by age in the 333 
reference , adiponectin or WPC groups, and an increase in that ratio at day 21 can only 334 
be observed in the leptin  group when comparing day 14 and day 21 (P<0.05) (Table 3). 335 
4. Discussion 336 
The neonatal benefits of the presence of leptin and adiponectin in breast milk are many; 337 
leptin have an important role in regulation of appetite, growth and weight and adiponectin 338 
was also associated inversely with obesity(15,29). Moreover, both adipokines were 339 
described to have immunomodulatory actions(18,30,31). However, at present, there are no 340 
studies on the influence of leptin and adiponectin on the immune system in early life, 341 
particularly on the immature GALT.  342 
The results of this study show that the adipokines supplementation did not modify the 343 
body weight gain pattern, the body mass index or the Lee index, suggesting that the 344 
administration of leptin and adiponectin did not modify the body mass of the animals. 345 
These results are in accordance with other studies performed with rats that were orally 346 
administered with leptin during the suckling period(22,32), and also in old male mice 347 
receiving subcutaneous doses of leptin(33). Taking into account the role of leptin in satiety 348 
and suppression of appetite described in adults(34,35), a weight loss would have been 349 
expected. However, studies in rats and mice suggest that leptin may have a different role 350 
in neonates because the exogenous administration of leptin to newborn rats modifies the 351 
expression of neuropeptides, known to affect appetite in adults, without altering appetite 352 
in neonatal rats(35). Furthermore, weight loss has been described as a potent inducer of 353 
adiponectin synthesis(36); however, there is almost no information regarding whether 354 
adiponectin affects, directly or indirectly, body weight in adults, and none at all regarding 355 
neonatal life. 356 
When the adipokines are administered, they travel through the gastrointestinal system and 357 
pass through the epithelial barrier into the blood(29). A limitation of this study is that the 358 
biodisponibility of leptin and adiponectin has not been measured in the suckling rats along 359 
the intervention. In addition, although recent studies show that different multimers of 360 
adiponectin can have different biological actions (38,39), we supplemented the rats with the 361 
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monomeric form, whereas the most abundant in human milk is the high molecular weight 362 
(HMW) multimeric form (15,40).  363 
Even though, as they reached the intestine there must be a direct interaction between these 364 
compounds and the intestinal epithelial cells as well as with the immune cells scattered 365 
throughout the intestine (effector sites) or grouped in aggregates (induction sites) of the 366 
GALT. For this reason, considered it would be interesting to determine the effect of 367 
adipokines on morphometric changes of the small intestine. Supplementation with leptin, 368 
but not with adiponectin, for the three weeks of suckling was able to increase the relative 369 
small intestine weight, therefore suggesting a certain local trophic effect of leptin on the 370 
intestine. However, when we considered the intestinal production of secretory IgA and 371 
IgM at the end of the suckling period, the levels were very low, far away from those 372 
described in six-week-old Wistar rats(41), and in agreement with studies showing the 373 
immaturity of B cells in the neonate(42). The supplementation with leptin, but not 374 
adiponectin, caused a reduction in the secretion of intestinal IgA without affecting IgM 375 
levels. These antibodies are produced by plasma cells stimulated under Th2 conditions(43). 376 
Some studies suggest the ability of leptin to stimulate Th1 responses and inhibit those of 377 
Th2(30,44). Thus, the reduction of intestinal secretory IgA associated with leptin 378 
supplementation could be attributed to this inhibitory effect. This effect was not observed 379 
in the case of adiponectin.  380 
During suckling, rats undergo phenotypical changes in intestinal lymphoid tissues that 381 
are a reflection of the immune system’s maturation in this period(4). Therefore, the study 382 
of MLN lymphocyte composition and functionality in neonates is a useful strategy for 383 
assessing the modulatory ability of leptin and adiponectin on the immune system. In this 384 
study, none of the adipokines affected B, NK or NKT populations in MLN lymphocytes. 385 
However, leptin significantly increased the proportion of TCRαβ+CD8+ lymphocytes in 386 
a similar way to the WPC, suggesting an early maturation of this subset. The increase in 387 
the TCRαβ+CD8+ cell proportion caused an increase in the overall T cell percentage. 388 
These results are in concordance with a study carried out by Oral et al. in human patients, 389 
in which an increase in the percentage of blood T cells and CD8+ subsets after leptin 390 
intake was found, without changing NK cell percentage(45). Moreover, another study in 391 
mice splenocytes and thymocytes also described an increase in CD8+ population after 392 
leptin administration(43). This increase in T lymphocytes induced by leptin could be 393 
explained by its suggested anti-apoptotic effect(47). Leptin promotes T cell survival by 394 
15 
 
modulating the expression of anti-apoptotic proteins, such as Bcl-xL in stress-induced 395 
apoptosis(48). The reason why this mechanism could be particularly affecting just the 396 
CD8+ subsets is yet to be established. On the other hand, little is known about the effect 397 
of adiponectin on lymphocyte subpopulations. We found here that adiponectin 398 
supplementation was also able to increase CD8+ cell percentage in MLN. This immune 399 
development-promoting effect found here is not in line with the negative regulation effect 400 
shown by Wilk et al.(49). In particular, they investigated the in vitro and in vivo effects of 401 
adiponectin in antigen-specific T-cell responses and evidenced an increase in 402 
CD137+CD8+ and CD137+CD4+ proportions in adiponectin knockout mice. CD137 is 403 
a costimulatory molecule expressed by activated T cells that enhances T cell proliferation, 404 
IL-2 secretion, survival and cytolytic activity(50). 405 
The proportion of cells bearing the adhesion molecules αE integrin and CD62L selectin 406 
related to the intestinal homing of lymphocytes has been also analysed. The surface αE 407 
integrin was practically non-existent in MLN lymphocytes, and the relative numbers of 408 
CD62L+ cells were high and age-related, being higher at the end of lactation. The 409 
presence of these molecules, involved in lymphocyte rolling and recruitment to peripheral 410 
lymphoid tissues, in early life rat MLN is similar to that in previous studies(28) and also 411 
in older animals(51). The supplementation with adipokine did not exert profound changes 412 
in the expression of these homing molecules with the exception of an decrease in the 413 
αE+CD62L+CD4+CD8+ percentage in animals supplemented with leptin, the 414 
significance of which remains to be explored.  415 
Regarding the MLN cell functionality, although not in this particular tissue, there are 416 
previous studies attributing to leptin the capacity to induce lymphoproliferation in vitro 417 
and in vivo(17,51–55). In contrast, with respect to the reference group we found no 418 
differences in lymphocytes from animals given leptin. Those animals supplemented with 419 
adiponectin had a higher proliferation rate than the reference group and similar values to 420 
those animals supplemented with WPC. Thus, it seems that adiponectin is able to 421 
accelerate the acquisition of this immune cell capacity in neonatal life. Conversely, Wilk 422 
et al. studied the effect of adiponectin on proliferation and apoptosis of antigen-specific 423 
T cells in vitro and showed an apoptosis-promoting effect on CD137+ subsets, which was 424 
not observed in CD137- subsets(49). 425 
The release of cytokines after in vitro stimulation of lymphocytes from leptin- or 426 
adiponectin-supplemented animals was also studied. Reported studies with leptin show 427 
16 
 
its ability to stimulate the production of Th1-related cytokines such as IL-1, IL-6, IL-12 428 
and TNF(30). Nevertheless, we found an increase in IL-4 and IL-5, Th2-type cytokines, at 429 
day 14 and a decrease of IL-2 and IL-12p70 levels at day 21 due to leptin 430 
supplementation. These results agree with an in vitro study showing that low 431 
concentrations of leptin increase IL-4 production(56). Overall, focusing on the Th1/Th2 432 
cytokine ratio (calculated as IFN-γ/IL-4 ratio), leptin increased the age-related ratio (day 433 
21 vs. day 14) thus reinforcing its suggested Th1-promoting and Th2-inhibiting role. In 434 
addition, adiponectin increased the release of IL-5, IL-13 and TNF-α at day 14 and 435 
decreased the secretion of IL-2, IL-12p70 and IL-13 at day 21. In consequence, it seems 436 
that adiponectin does not have a clear Th1/Th2-promoting effect. However, it has been 437 
described that adiponectin reduced the expression of the TNF-α in arterial and adipose 438 
tissues(57,58). Furthermore, in human monocyte-derived macrophages, adiponectin inhibits 439 
the expression of IL-6 as well as TNF-α but increases the levels of IL-10(59). Overall, 440 
further studies should be carried out to fully elucidate the contribution of these adipokines 441 
to the cytokine secretion in this period of life. 442 
In summary, the results obtained here suggest that dietary supplementation with leptin 443 
and adiponectin during the suckling period is able to promote the maturation of the 444 
intestinal immune system. A daily supplementation with leptin induces a rise in the 445 
intestinal weight and in the proportion of T cells in MLN, suggesting an intestinal trophic 446 
and immunomodulatory effect. Moreover, adiponectin is also able to increase the CD8+ 447 
percentage and to promote a proliferative response in MLN cells. Both leptin and 448 
adiponectin modulate the production of Th1 and Th2 cytokines. This demonstrates the 449 
capacity of these adipokines to promote the development and maturation of cells involved 450 
in adaptive immune response, which is clearly immature at this stage of life.  451 
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FIGURE LEGENDS 609 
Figure 1. Supplementation effect on secretory IgA and IgM content in the intestinal compartment 610 
(gut wash) at the end of the suckling period (day 21) from the four 4 groups: reference, leptin, 611 
adiponectin and whey protein concentrate (WPC). Results are expressed as mean ± S.E.M. (n = 612 
9–12 pups per group analyzed in duplicates). Statistical differences: * P<0.05 vs. reference group. 613 
Ψ P<0.05 vs. adiponectin group (Mann-Whitney U).  614 
Figure 2. Percentage of CD8+ cell subset (a) and CD8αα/CD8αβ ratio (b) in mesenteric lymph 615 
node lymphocytes during (day 14) and at the end (day 21) of the suckling period from the 4 four  616 
groups: reference, leptin, adiponectin and whey protein concentrate (WPC). Results are expressed 617 
as mean ± S.E.M. (n = 9–12 pups per group analysed in uniplicates). Statistical differences: 618 
* P<0.05 vs. reference group. ‡ P<0.05 vs. same group at day 14 (ANOVA). 619 
Figure 3. Supplementation effect on proliferation rate at day 14 and at day 21 in mitogen-620 
stimulated MLN lymphocytes from the four 4 groups: reference, leptin, adiponectin, and whey 621 
protein concentrate group (WPC). Results are expressed as mean ± S.E.M. (n = 3–9 pups per 622 
group analysed in quadruplicates). Statistical differences: * P<0.05 vs. reference group. § P<0.05 623 
vs. leptin group (Mann-Whitney U). 624 
  625 
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Table 1. Body mass index (BMI), Lee index, relative small intestinal (SI) weight and relative SI 626 
length in the four groups over the study (day 10, 14 and 21).  The BMI was calculated as body 627 
weight/length2 (g/cm2) and the Lee index, calculated as 3√ weight/length x 1000 (3√g/cm). 628 
Relative SI weight and relative SI length was calculated as weight/length of the intestine divided 629 
by the body weight x 100.  630 
WPC, whey protein concentrate. Data are expressed as mean ± S.E.M. (n = 7-15). Statistical 631 
differences: * P<0.05 vs. reference group. † P<0.05 vs. same group at day 10. ‡ P<0.05 vs. same 632 
group at day 14. § P<0.05 vs. leptin group (ANOVA). 633 
 634 
 635 









length  (%) 
Day 
10 
Reference 0.3 ± 0.0 337.4 ± 4.2 3.3 ± 0.1 158.1 ± 5.9  
Leptin 0.3 ± 0.0 335.9 ± 3.6 3.2 ± 0.0 164.8 ± 8.4  
Adiponectin 0.3 ± 0.0 341.9 ± 3.2 3.0 ± 0.0 162.1 ± 5.4  
WPC 0.3 ± 0.0 337.2 ± 2.9 3.2 ± 0.1 171.0 ± 7.7  
Day 
14 
Reference 0.4 ± 0.0 † 335.5 ± 2.6 3.3 ± 0.1        116.4 ± 2.4 †  
Leptin 0.4 ± 0.0 † 335.5 ± 3.1 3.4 ± 0.0 † 119.1 ± 7.6 †  
Adiponectin 0.4 ± 0.0 † 3354.0 ± 2.2 3.3 ± 0.0 † 122.3 ± 4.1 †  
WPC 0.4 ± 0.0 † 336.0 ± 3.6 3.4 ± 0.1   121.8 ± 5.3 †  
Day 
21 
Reference 0.4 ± 0.0 † 314.5 ± 3.3 †‡ 4.4 ± 0.1 †‡ 86.9 ± 2.3 †‡ 
Leptin 0.4 ± 0.0 † 316.3 ± 5.7 †‡ 5.3 ± 0.1 *†‡ 94.4 ± 4.0 †‡ 
Adiponectin 0.4 ± 0.0 † 314.1 ± 4.4 †‡ 4.6 ± 0.3 †‡§ 92.8 ± 3.8 †‡ 
WPC 0.4 ± 0.0 † 314.8 ± 6.2 †‡ 4.4 ± 0.1 †‡§ 96.6 ± 3.0 †‡ 
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Table 2. Main lymphocyte subsets in mesenteric lymph nodes in the four groups during (day 14) 637 
and at the end (day 21) of the suckling period.  638 
 639 
WPC, whey protein concentrate. Values are expressed as mean ± S.E.M. (n = 8-14 pups per group 640 
analyzed in uniplicates). Statistical differences: * P<0.05 vs. reference group. ‡ P<0.05 vs. same 641 
group at day 14.  (ANOVA). 642 
643 
 Day 14 
 Reference Leptin Adiponectin WPC 
T cells (%) 67.6 ± 2.0 76.4 ± 1.9 * 74.3 ± 2.2 75.6 ± 1.9 * 
  TCRαβ+ (%) 65.4 ± 2.0 74.0 ± 2.0 * 71.6 ± 2.2 73.1 ± 1.8 * 
  TCRαβ+ CD8+ (%) 18.4 ± 0.8 21.9 ± 1.3 * 20.1 ± 0.9 21.0 ± 0.7 * 
  TCRγδ+ (%) 2.2 ± 0.1 2.4 ± 0.1 2.7 ± 0.2 2.4 ± 0.2 
  TCRγδ+ CD8+ (%) 1.7 ± 0.1 1.9 ± 0.1 2.0 ± 0.2 1.9 ± 0.1 
  Th (%) (TCRαβ+CD8-CD4+) 47.0 ± 1.5 51.0 ± 2.1 51.5 ± 2.1 52.1 ± 1.3 
  T reg (%) - - - - 
NK (%) 1.2 ± 0.1 1.6 ± 0.3 1.2 ± 0.1 1.3 ± 0.1 
  NK CD8+ (%) 0.5 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 
NKT (%) 1.6 ± 0.2 2.2 ± 0.3 1.7 ± 0.2 1.8 ± 0.2 
  NKT CD8+ (%) 1.0 0 ± 0.1 1.4 ± 0.2 1.0 ± 0.1 1.1 ± 0.1 
B (%) 18.7 ± 1.3 16.9 ± 1.6 16.3 ± 1.4 16.2 ± 1.1 
CD8+CD4+ (%) 2.3 ± 0.4 2.8 ± 0.2 2.2 ± 0.1 2.4 ± 0.2 
 Day 21 
T cells (%) 70.4 ± 2.1 74.3 ± 2.5 71.8 ± 2.6 71.0 ± 2.3 
  TCRαβ+ (%) 67.5 ± 2.1 71.9 ± 2.7 69.0 ± 2.8 68.1 ± 2.4 
  TCR+ CD8+ (%) 19.5 ± 0.7 21.4 ± 1.4 21.2 ± 1.3 21.5 ± 1.2 
  TCRγδ+ (%) 3.0 ± 0.2 ‡ 2.5 ± 0.3 2.8± 0.3 2.8 ± 0.2 
  TCRγδ+ CD8+ (%) 2.4 ± 0.2 ‡ 1.9 ± 0.1 2.1 ± 0.2 2.1 ± 0.2 
  Th (%)(TCRαβ+CD8-CD4+) 48.0 ± 1.5 50.5 ± 1.6 47.9 ± 1.6 46.7 ± 1.7 ‡ 
  T reg (%) 4.2 ± 0.2 4.4 ± 0.2 4.6 ± 0.2 4.1 ± 0.3 
NK (%) 0.9 ± 0.1 ‡ 0.7 ± 0.1 ‡ 0.8 ± 0.1 ‡ 0.9 ± 0.1 ‡ 
  NK CD8+ (%) 0.3 ± 0.0 0.2 ± 0.0 ‡   0.4 ± 0.1 0.3 ± 0.1 
NKT (%) 1.7 ± 0.2 1.3 ± 0.2 ‡ 1.8 ± 0.3 1.8 ± 0.2 
  NKT CD8+ (%) 0.9 ± 0.1 0.7 ± 0.1 ‡ 1.1 ± 0.2 1.1 ± 0.1 
B (%) 17.3 ± 1.9 13.7 ± 1.6 17.0 ± 1.9 16.5± 1.7 
CD8+CD4+ (%) 2.2 ± 0.1 2.4 ± 0.2 2.4 ± 0.1 2.2 ± 0.1 
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Table 3. Cytokine production from mesenteric lymph node lymphocytes in the four groups over 644 
the study (day 14 and 21).  645 
 646 
 Day 14 
Cytokines 
(pg/mL) 
Reference Leptin Adiponectin WPC 
IL-1α  24.1 ± 8.0 34.5 ± 10.7 50.7 ± 5.4 18.0 ± 5.8 
IL-2 321.2 ± 244.9 389.9 ± 163.9 1540.3 ± 732.7 1101.8 ± 931.8 
IL-4  108.5 ± 18.3 225.4 ± 40.4 * 156.6 ± 24.2 70.4 ± 5.1 §  
IL-5  1.3 ± 0.3 5.1 ± 0.9 * 7.7 ± 2.2 * 1.9 ± 0.6 
IL-10  7147.5 ± 1452.3 6951.3 ± 950.8 7916.7 ± 1563.8 5075.1 ± 1493.8 
IL-12p70  6.8 ± 1.4 8.6 ± 3.1 12.0 ± 0.9 8.6 ± 3.1 
IL-13  30.1 ± 9.5 54.9 ± 17.2 85.8 ± 21.9 * 21.0 ± 10.0 
IL-17A  33.1 ± 17.1 30.4 ± 13.4 92.8 ± 42.9 29.5 ± 11.8 
INF-γ   14314.0 ± 8273.3 9281.4 ± 1495.3 14181.8 ± 2665.5 6059.8 ± 1516.1 
TNF-α  6.1 ± 1.6 6.7 ± 2.9 16.2 ± 21.0 * 6.9 ± 2.7 
IL-10/TNF-α  1943.5 ± 710.1 1954.4 ± 1179.0 551.5 ± 173.3 1148.7 ± 546.3 
INF-γ /IL-4  113.2 ± 45.9 46.0 ± 14.2 106.9 ± 35.7 83.8 ± 16.0 
 Day 21 
IL-1α  6.5 ± 0.0 ‡ 8.2 ± 1.3 ‡ 9.0 ± 1.3 ‡ 7.9 ± 0.7 ‡ 
IL-2  716.7 ± 210.2 54.6 ± 6.3 *‡ 120.4 ± 53.9 *‡ 636.7 ± 176.4 
IL-4  86.2 ± 9.5 50.9 ± 9.4 ‡ 63.1 ± 17.0 ‡ 70.4 ± 12.2 
IL-5  1.8 ± 0.3 1.4 ± 0.5 ‡ 1.3 ± 0.4 ‡ 2.3 ± 1.0 
IL-10  2745.8 ± 356.8 ‡ 3060.2 ± 613.7 ‡ 1971.0 ± 475.7 ‡ 2084.9 ± 255.2 ‡ 
IL-12p70 13.8 ± 3.7 4.3 ± 1.2 * 2.5 ± 0.0 *‡ 2.5 ± 0.0 *‡ 
IL-13  14.0 ± 2.3 ‡ 7.7 ± 2.5 ‡ 6.0 ± 1.4 *‡ 8.4 ± 1.4 
IL-17A  58.7 ± 11.0 45.8 ± 8.7 37.7 ± 8.7 64.1 ± 10.8 
INF-γ   7090.1 ± 581.2 7407.5 ± 853.2 7043.1 ± 744.0 ‡ 5424.3 ± 375.5 
TNF-α  11.5 ± 1.6 ‡ 8.8 ± 0.9 8.6 ± 0.5 ‡ 8.9 ± 0.5 
IL10/TNF-α  271.7 ± 49.1 ‡ 357.0 ± 72.2 ‡ 232.6 ± 51.9 ‡ 231.9 ± 20.0 ‡ 
INF-γ /IL-4  106.1 ± 21.1 167.1 ± 34.8 ‡  195.2 ± 77.9 108.6 ± 29.0 
 647 
WPC, whey protein concentrate. Values are expressed as mean ± S.E.M. (n = 3-12 pups per 648 
group analyzed in duplicates). Statistical differences: * P<0.05 vs. reference group. ‡ P<0.05 vs. 649 
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Suppl. Table 1. Expression of the αE integrin and the CD62L selectin in Th cells (CD4+CD8-), 690 
DP cells (CD4+CD8+), Tc (CD8+CD4-) and B (CD45RA+) lymphocytes in mesenteric lymph 691 
nodes from the four groups of the study.  692 
 693 
WPC, whey protein concentrate. Values are expressed as mean ± S.E.M. (n = 8-14 pups per 694 
group analyzed in uniplicates). Statistical differences: * P<0.05 vs. reference R group 695 
(ANOVA). ‡ P<0.05 vs. same group data at day 14 (ANOVA). 696 
 697 
  698 
 












Reference 1.1 ± 0.2 3.0 ± 0.8 1.5 ± 0.2 3.4 ± 1.0 
Leptin 1.0 ± 0.5 2.6 ± 0.7 1.3 ± 0.4 1.1 ± 0.5 
Adiponectin 0.7 ± 0.1 2.1 ± 0.5 1.7 ± 0.2 2.3 ± 0.7 




Reference 0.6 ± 0.2 6.0 ± 1.1 1.6 ± 0.4 0.5 ± 0.2 
Leptin 0.4 ± 0.1 3.8 ± 1.0 0.7 ± 0.4 1.2 ± 0.7 
Adiponectin 0.3 ± 0.1 3.9 ± 0.6 1.0 ± 0.2 1.1 ± 0.4 




Reference 55.1 ± 1.8 68.6 ± 2.1 62.0 ± 2.4 35.0 ± 4.6 
    Leptin      54.6 ± 2.6   70.0 ± 2.2   58.7 ± 2.2    45.6 ± 6.4 
Adiponectin 52.0 ± 1.9 68.7 ± 1.2 60.3 ± 1.6 43.9 ± 3.8 




Reference 43.3 ± 2.0 22.4 ± 2.1 34.9 ± 2.8 61.1 ± 4.8 
Leptin 44.1 ± 2.3 23.7 ± 1.6 39.4 ± 2.4 52.1 ± 6.3 
Adiponectin 47.0 ± 2.0 25.3 ± 1.2 37.0 ± 1.5 52.7 ± 4.1 





Reference 1.3 ± 0.2 3.9 ± 1.0 1.0 ± 0.1 3.1 ± 0.8 
Leptin 0.9 ± 0.1 2.5 ± 0.6 1.5 ± 0.8 2.0 ± 0.7 
Adiponectin 1.1 ± 0.1‡ 2.9 ± 0.9 3.9 ± 1.8 2.6 ± 0.7 




Reference 0.8 ± 0.2 5.2 ± 0.9 1.2 ± 0.3 0.3 ± 0.1 
Leptin 0.5 ± 0.1 2.3 ± 0.2* 0.7 ± 0.2 0.2 ± 0.1 
Adiponectin 0.6 ± 0.1‡ 3.2 ± 0.5 1.1 ± 0.2 0.4 ± 0.1 




Reference 61.6 ± 1.7 ‡ 70.8 ± 2.4 65.9 ± 2.4 53.4 ± 3.2 ‡ 
Leptin 60.4 ± 1.8 73.5 ± 1.6 63.6 ± 2.0 54.0 ± 4.9 
Adiponectin 57.4 ± 2.5 73.6 ± 3.2 60.4 ± 3.0 59.2 ± 2.8 ‡ 




Reference 36.2 ± 2.0 ‡ 20.5 ± 2.0 31.9 ± 2.3 43.2 ± 2.8 ‡ 
Leptin 38.3 ± 1.6 21.6 ± 1.4 34.3 ± 1.7 43.8 ± 4.9 
Adiponectin 40.9 ± 2.4 20.4 ± 2.4 34.6 ± 2.9 37.8 ± 2.5 ‡ 
WPC 40.4 ± 1.5 ‡ 22.2 ± 1.7 32.7 ± 2.4 38.0 ± 3.6 ‡ 
30 
 
Suppl.Figure 1. Rat body weight gain during the suckling period from the four groups Reference, 699 
leptin, adiponectin and whey protein concentrate (WPC). Results are expressed as percentage of 700 
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Age (days)























Suppl. Figure 2. Representative histograms of the CD62L selectin/αE integrin pattern in the total 713 
lymphocytes from the mesenteric lymph nodes of reference (a), leptin (b), adiponectin (c) and 714 
whey protein (WPC) (d) groups at day 21. In each quadrant the values expressed as mean ± S.E.M. 715 
(n = 9–12 pups per group analyzed in uniplicates) are included. Statistical differences: ‡ <0.05 vs. 716 
same group at day 14 (ANOVA). 717 
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61.5 ± 1.7 ‡  1.0 ± 0.2 
35.9 ± 1.7 ‡ 1.6 ± 0.2 
(a) Reference – Day 21 
60.9 ± 1.6 ‡  0.5 ± 0.1 
37.2 ± 1.4 ‡ 1.4 ± 0.3 
(b) Leptin – Day 21 
56.7 ± 2.4 0.8 ± 0.1 
40.1 ± 2.2 ‡ 2.5 ± 0.7 
(c) Adiponectin – Day 21 
58.9 ± 1.3 ‡ 0.7 ± 0.1 
38.7 ± 1.5 ‡ 1.9 ± 0.6 
(d) WPC – Day 21 
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